Effect of Chinese Hebal Compound of Different Treating Principles on uPA of Cholestasis-induced Liver Fibrosis Rat
- VernacularTitle:不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响
- Author:
Deming AN
;
Peiyong ZHENG
;
Guang JI
- Publication Type:Journal Article
- Keywords:
cholestasis-induced liver fibrosis;
Erzhiwan;
Shixiaosan;
uPA;
western blot;
rat
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2006;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of the Chinese herbal compound (Erzhiwan, Shixiaosan and combined formula) on cholestasis-induced liver fibrosis rat’s uPA. Methods Bile duct ligation method was used to make the model of cholestasis-induced liver fibrosis. One week after the operation, the rats were randomly divided into five group (model group, UDCA group, Erzhiwan group, Shixiaosan group and hefang group). Each medicine intervention group was given corresponding medicine by intragastric administration. Sham and model group were given sodium chloride with equal dosage. At the end of 4th week, all rats were sacrificed and sampled. General state of health, hepatic function (ALT, AST, ALP, TBil) and pathological histology of hepatic tissue were recorded and measured. Results Compared with the sham group, the level of ALT, AST, ALP, TBil and the degree of liver fibrosis in model group were advanced significantly. Compared with model group, three Chinese herbal compound decreased serum level of ALP, ALT and AST (P
